Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

50%

2 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
1(25.0%)
Phase 3
1(25.0%)
Phase 4
1(25.0%)
Early Phase 1
1(25.0%)
4Total
Phase 2(1)
Phase 3(1)
Phase 4(1)
Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT00817037Phase 2Completed

Sitaxsentan in Proteinuric Chronic Kidney Disease

Role: collaborator

NCT01100736Early Phase 1Completed

Role of Endothelin-A (ETA) and Endothelin-B (ETB) Receptors in the Vasodilatory Response to Endothelin-3 (ET-3)

Role: collaborator

NCT00080457Phase 3Completed

Safety and Efficacy Study of Sitaxentan Sodium (Thelin™) in Patients With Pulmonary Arterial Hypertension

Role: lead

NCT00039858Phase 4Completed

Evaluation of Argatroban Injection in Pediatric Patients Requiring Anticoagulant Alternatives to Heparin

Role: lead

All 4 trials loaded